Theratechnologies Has Filed A Supplemental Biologics License Application For The F8 Formulation Of Tesamorelin To The FDA For Review
Portfolio Pulse from Benzinga Newsdesk
Theratechnologies has submitted a supplemental Biologics License Application for the F8 formulation of Tesamorelin to the FDA for review. Tesamorelin is the only medication approved in the U.S. for reducing excess abdominal fat in adults with HIV who have lipodystrophy.
September 25, 2023 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theratechnologies has filed a supplemental application with the FDA for Tesamorelin, a unique medication for reducing abdominal fat in HIV patients with lipodystrophy.
The filing of a supplemental Biologics License Application indicates that Theratechnologies is seeking to expand the use of Tesamorelin. If approved, this could potentially increase the company's market share and revenues, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100